Corcept Therapeutics Incorporated (CORT) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Total Assets Chart for Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated (CORT) total assets for FY2025 were USD 836.7M, a -0.5% change from FY2024. Corcept Therapeutics Incorporated's total assets grew from USD 1.0M in 2000 to USD 836.7M in 2025 (79885.8% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 7.9%, 10-year CAGR of 32.0%, 20-year CAGR of 18.1%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$12.93B
Implied Share Price
$119.57
Enterprise Value
$11.89B
Revenue (TTM)
$830.81M
EBITDA
$8.08M
Profit Margin
6.64%
Trailing P/E
271.75
Forward P/E
19.30
Price/Book (MRQ)
18.00
Price/Sales (TTM)
15.56
EV/EBITDA
1405.48
EV/Revenue
14.93
Dividend Yield
—
Book Value
$6.54
Free Cash Flow (FY2025)
$141.78M
Free Cash Flow Yield
1.10%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.